Olema Pharmaceuticals
Olema Pharmaceuticals Inc is an American clinical-stage biopharmaceutical company focused on the discovery, development, and commercialization of targeted therapies for women's cancers, prominently featuring its proprietary oral selective estrogen receptor degrader (SERD) candidate, palazestrant, designed for the treatment of estrogen receptor-positive (ER+) advanced breast cancer. The company conducts advanced clinical trials evaluating novel oncology therapeutics intended to overcome treatment resistance in metastatic breast cancer patients. Its core business operations encompass biopharmaceutical oncology research, drug discovery, clinical trial execution, and pharmaceutical development. As a clinical-stage biotechnology enterprise, the company generates minimal commercial revenue and finances its ongoing operational activities through public equity offerings and strategic biopharmaceutical research collaborations. Olema Pharmaceuticals holds a pioneering market position in targeted breast cancer therapeutics. The company is headquartered in San Francisco, California, United States, and its common stock trades on the Nasdaq Global Select Market.
7 of the funds FundTelligence covers report a position in Olema Pharmaceuticals.
- Legal name
- Olema Pharmaceuticals Inc
- Sector
- Health Care
- Country
- United States
- Funds holding it
- 7
Funds holding Olema Pharmaceuticals
- Franklin Biotechnology Discovery Fund — Franklin Templeton · 0.42 % (full portfolio disclosed, September 2026)
- SEB Läkemedelsfond — SEB · 0.24 % (full portfolio disclosed, June 2026)
- Schroder ISF Healthcare Innovation — Schroders · 0.22 % (full portfolio disclosed, June 2026)
- BlackRock iShares NASDAQ US Biotechnology UCITS ETF — BlackRock · 0.04 % (full portfolio disclosed, October 2026)
- Swedbank Robur Healthcare — Swedbank · 0.02 % (full portfolio disclosed, October 2026)
- KLP AksjeGlobal Small Cap Indeks — KLP · 0.01 % (partially disclosed portfolio, June 2026)
- DNB Global Enhanced Small Cap — DNB · 0.0 % (full portfolio disclosed, September 2026)